Treatment of malignant hypercalcaemia with clodronate
Open Access
- 1 May 1985
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 51 (5), 665-669
- https://doi.org/10.1038/bjc.1985.100
Abstract
We have assessed the effects of clodronate (dichloromethylene diphosphonate; Cl2MDP 0.8-3.2g daily by mouth for up to 3 months) in 17 episodes of hypercalcaemia and osteolysis due to carcinoma. Clodronate reduced serum calcium in 14 episodes and bone resorption in all patients. These remained suppressed for the duration of treatment, but recurred promptly when treatment was stopped. Clodronate may be a useful measure for controlling hypercalcaemia and osteolysis in patients with carcinoma.Keywords
This publication has 24 references indexed in Scilit:
- Role of glucocorticoids in management of malignant hypercalcaemia.BMJ, 1984
- The Hypercalcemia of CancerNew England Journal of Medicine, 1984
- Treatment of hypercalcaemia associated with malignancy.BMJ, 1984
- Use of Dichloromethylene Diphosphonate in Metastatic Bone DiseaseNew England Journal of Medicine, 1983
- EFFECTS OF INTRAVENOUS DIPHOSPHONATES ON RENAL FUNCTIONThe Lancet, 1983
- The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myelomaBritish Journal of Haematology, 1983
- Human renal carcinoma cells produce hypercalcemia in the nude mouse and a novel protein recognized by parathyroid hormone receptors.Journal of Clinical Investigation, 1983
- LONG-TERM CONTROLLED TRIAL WITH DIPHOSPHONATE IN PATIENTS WITH OSTEOLYTIC BONE METASTASESThe Lancet, 1983
- EFFECT OF DICHLOROMETHYLENE DIPHOSPHONATE IN PAGET'S DISEASE OF BONE AND IN HYPERCALCÆMIA DUE TO PRIMARY HYPERPARATHYROIDISM OR MALIGNANT DISEASEThe Lancet, 1980
- Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.Journal of Clinical Investigation, 1980